PRTODAY / NewswireToday Free press release distribution service network

More news: Health/Surgery
Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Pipeline Products Could Improve Treatment of Diabetes & Create New Sources of Growth for the Market - Diabetes is a growing epidemic in the United States, with the number of people diagnosed with the disease increasing more than two-fold over the past 15 years
Pipeline Products Could Improve Treatment of Diabetes & Create New Sources of Growth for the Market

 

NewswireToday - /newswire/ - Palo Alto, CA, United States, 2007/02/06 - Diabetes is a growing epidemic in the United States, with the number of people diagnosed with the disease increasing more than two-fold over the past 15 years.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

New analysis from Frost & Sullivan, U.S. Diabetes Pipeline Outlook, reveals that more than 70 drugs are currently in clinical development for diabetes. Additionally, it provides discussion and analysis on the leading areas in the diabetes pipeline, including class dynamics and competitive factors for new product types.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Diabetes Pipeline Outlook, then send an e-mail to Melina Trevino - Corporate Communications with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.

“New pipeline technologies have the potential to positively change diabetes therapy,” says Frost & Sullivan Industry Manager Daniel Ruppar. “They also have the ability to create new treatment options and pathways for patients and physicians.”

Diabetes is currently an area of unmet medical need. Multiple new product types with the potential to improve diabetes therapy are currently in clinical development. Additionally, new technology products, such as Byetta, Januvia, and Exubera, are leading the way as first-in-class drugs that could make a positive impact in the near term.

Pharmaceutical companies are constantly seeking new drugs that can improve the treatment of diabetes and create new sources for revenue growth. In order to be successful, new products must differentiate themselves from current therapies. Furthermore, they must demonstrate advantages in characteristics such as efficacy and safety. In order for the healthcare community and payers to embrace new product technologies, the therapeutic ROI must be well outlined and demonstrated.

“New diabetes products are of high interest to physicians and patients,” explains Ruppar. “However, the industry must effectively demonstrate the benefits of these new technologies over current treatments in order for them to find their niche.”

To judge how a novel product might fare in the marketplace, it is essential that they demonstrate how they can work with, improve upon, or replace current products. Diabetes drugs that are in the pipeline today could improve treatment outcomes and greatly help patients in the future fight the disease.

The U.S. Diabetes Pipeline Outlook is part of the Pharmaceutical & Biotechnology Growth Partnership Service, and provides insight and discussion of the drugs in clinical development for diabetes treatment in the United States. In this study, Frost & Sullivan's expert analysts thoroughly examine the following technologies: GLP-1 Agonists, DPP-IV inhibitors, pulmonary insulin, PPAR modulators, and other pipeline efforts. Interviews are available to the press.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


Pipeline Products Could Improve Treatment of Diabetes & Create New Sources of Growth for the Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Melina Trevino 
210-247-2440 melina.trevino[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Health/Surgery Most Recent Related Newswires:

Xenex Receives Top Honors from Frost & Sullivan for LightStrike™ - the Only Pulsed Xenon UV Disinfection System in the Healthcare Market
Partners HealthCare and GE Healthcare Launch 10-year Collaboration to Integrate Artificial Intelligence into Every Aspect of the Patient Journey
US Acute Care Solutions Celebrates 2-Year Anniversary
GE Healthcare Receives FDA Indication Approval for Visipaque™ (iodixanol) Injection for use with Coronary CT Angiography
Telehealth Vendors Expand mHealth Portfolio to Conquer New Growth Opportunities Finds Frost & Sullivan
GE Healthcare Acquires Asymptote for Complete, Digitally-enabled Cryogenic Cold Chain Technology Supporting Safe Manufacture And Delivery Of Cellular
ANVISA Approval for EMCM Facilitates the Progress of Leader Biomedical Operations in Brazil
GE Healthcare Expands Digital Maternal-Infant Care Offerings with Acquisition of Monica Healthcare
Next-generation Natural Materials to Replace Traditional Synthetic Materials in Personal Care Products Finds Frost & Sullivan
Digital Innovation-driven Diagnostic Advances Transform Smart Healthcare Finds Frost & Sullivan
Hospitals’ Outsourcing of Sterile Processing Expand Opportunities for Third Party Service Providers in the US & Western Europe Finds Frost & Sullivan
Emerging Cardiac Therapies Catalysed by Innovative Product and Next-generation Technology Finds Frost & Sullivan
Austrian Centre of Industrial Biotechnology and GE Healthcare Establish A Cell Line Engineering Collaboration
Sequencing Platform Providers Aim to Develop Tests for Infectious Diseases to Expand Market Opportunity Finds Frost & Sullivan
Arcadia Wins Top Honors from Frost & Sullivan for its Next-generation Clinical and Claims Analytics Platform, Arcadia Analytics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Deb Sheppard - Medium Psychic Author Speaker





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)